Q1 2022 Univar Solutions Inc Earnings Call
We moved by the generosity empathy and support being shown by people and companies all around the world.
We to update our own contribution to the international community the Red Cross to aid refugees in the region.
From a business perspective, we fully support the international trade sanctions that have been imposed and we have already exited our Russian operation, which were less than 1% of our sales.
Moving to the key highlights from the quarter, we delivered record Q1, net income of $191 million and adjusted EBITDA of $319 million.
Market share expanded in the quarter as evidenced by our policy of win loss ratio and high retention levels for new customers.
Our sales of higher margin ingredients in specialties increased driven by strong demand and new supplier authorizations.
Our digital investments are yielding real benefits with 47% of our U S customers now registered on our e-commerce channels and able to utilize $24 seven self service capabilities.
We continue to evaluate M&A opportunities that we could grow at a high organic rates by leveraging our infrastructure and global scale.
Returned $24 million of capital to shareholders via share repurchases.
In the first quarter, we continued our trend of outpacing the prior year in large part due to our committed market position in key products as well as utilizing our extensive network of facilities and the advantages of our owned trucking and rail fleet.
We believe our core value proposition of providing security of supply safely so our customers and sound product stewardship to our suppliers has allowed us to win new market share.
Looking at the end markets, we saw impressive sales growth across all four of our geographic reporting segments.
In our ingredients and specialty channel beauty and personal care revenue growth has accelerated with ongoing productivity outages impacting price, particularly within the skin and hair care industries.
Pharmaceuticals continues to deliver strong results from new product authorizations and increased demand for high purity solvents, excipient and active pharmaceutical ingredients.
Within our case portfolio, we saw a persistent demand for paints and coatings and construction related chemistries supported by our extensive line card and technical capabilities as the market expands around more sustainable solutions.
Specialty surfactants within our homecare and industrial cleaning along with our enzyme portfolio are delivering year over year growth as these broker lubricants and fleet business.
A volatile customers continues to evolve as we formulate solutions with the growth trends in the market and support the demand for more sustainable solutions and clean label ingredients.
Within our chemicals and services channel, we saw strong growth across a variety of industrial end markets with continued strength in chemical manufacturing water and mining chemistries driven by ongoing supply tightness and high market demand.
Our extensive organic chemistry portfolio has supported growth in these segments, while the ability to leverage our scale.
Although now a much smaller part of our business.
As higher oil prices and et cetera.
Production with increased customer demand for more sustainable solutions in this sector market is to leverage.
Distribution capabilities and provide.
At full lifecycle chemical product management for 2022, and amidst growing macro economic uncertainties. We remain focused on factors we can control.
We are confident that our chosen strategic priorities, coupled with our operational execution abilities will drive expected market share growth and deliver strong results, even as chemical pricing metal stabilized through the year.
Accordingly for Q2, 2022, we estimate an adjusted EBITDA guidance for $270 million to $290 million.
<unk> increased our guidance for the full year 2022 to one to one to one $5 billion with resulting strong cash flows.
Looking further ahead to 2023 and while it's not giving firm guidance at this point, we expect to bring forward the financial targets write downs at last November's analyst day, delivering a full year ahead of schedule.
We believe our dual focus on the customer experience and market share growth as we leverage our asset base, our extensive private transportation fleets digital capabilities and our long standing commitment to our ESG goals positions us for continued success.
We are perfectly positioned to capitalize on the evolving global trends such as local sourcing sustainable solutions and Digitization and believe we have the right people products tools and strategy to grow our delivered gross profit rates greater than general consensus of the economy and as such believe we are in a strong position.
<unk> to build a long term sustainable shareholder value.
Now, let me turn the call over to Nick who will walk you through our first quarter results and our outlook before I comment on our key strategies and we get to your questions.
Thank you David I.
I am pleased to share Universe solutions Q1 financial results update you on our business activities and review our revised outlook for 2022.
Sales were up around 37% on a constant currency basis.
Excluding results of divestitures from prior year's financials and adjusting for the recent Latam acquisition, we estimate net sales to be up 39% and a corresponding gross profit was also up 39% on a constant currency basis.
These growth rates were primarily impacted by chemical price inflation, as well as higher industrial demand and market share gains.
First quarter adjusted EBITDA of $319 million was up by 80% on a constant currency basis, primarily driven by the higher gross profit.
Gross profit growth was partially offset by operating expenses, reflecting higher variable compensation, but benefited by $9 million environmental recovery and $10 million and net synergies.
For a detailed schedule in the appendix adjusted earnings per diluted share were $1 seven in the quarter and increased from 43 in the prior year's first quarter.
Operating cash use of $134 million was higher versus the prior year period, primarily due to the net working capital use and the variable comp.
Compensation payout relating to the 2021 performance.
Net working capital rose to 15% of quarterly sales annualized reflecting the higher raw material costs impacting both inventories and accounts receivable balances.
Capital expenditures for the quarter were 33 million and as we've previously indicated there were no further next year integration related expenses. As these were all completed in Q4 of 2021.
Our ROIC was 19, 7% for the quarter driven by a strong performance and efficient asset utilization and net debt leverage now stands at two four times within our stated goal range of two to two five times.
These ratios are net of a further $24 million of cash returned to shareholders. During the first quarter through our share repurchase program.
On slide eight we have aggregated the key metrics across our four reporting segments and we'll provide details in the appendix.
Sales were higher across all geographies, primarily benefiting from chemical pricing industrial demand and market share gains.
EMEA results were partially offset by the district will divestiture, whereas Latam results benefited from Street Vicks acquisition.
Gross profit and adjusted EBITDA grew across all the regions with strong margins.
In EMEA gross profit margins were more impacted by the relative cost inflation, whereas Latam imperatives were impacted by a richer mix in Q1 of last year.
Latam EBITDA margins were lower as we have reallocated corporate costs and we reflect the SDP implementation in the current year.
Turning to our 2022 outlook, we generally expect stable end market demand throughout the year continued market share gains and solid operational execution relation to stabilize and the related pricing benefits in margin.
Surgeons to moderate in the second half we are continuing to make.
Monitor supply chain complexities geopolitical uncertainties and any size.
Signs of recessions.
We estimate the net nonrecurring margin benefit from the pricing in 2022 to be $100 million to $110 million, which we expect to be predominantly reflected in the first half of the year's EBITDA.
In excess of our initial forecast by around $45 million in 2022, which will be reflected.
Okay ratably through the year.
Accounting for all these factors is a range of 270.
$1 million to $290 million.
So we have increased our adjusted EPS.
So does that guidance to $1 billion to $1 50.
As David noted we have confidence.
Turning to our ability to execute and grow share and we are bringing forward our 2024th annual state financial targets, which included.
Included in adjusted EBITDA of $960 million and a better than 9% margin into 2023, a year ahead of schedule.
This reflects our estimates that in general 2021, chemical pricing levels are the prevailing level versus the prior view of having 2019 as our base level.
As mentioned previously we plan to utilize our authorized share repurchase program to buyback amounts related to executive compensation dilution at a minimum and are guiding a diluted share count range of a 171 2022.
Let's review some of the cash flow highlights of our 2020 outlook.
We will continue to target net working capital of 13, 5% to 14% we have been ending the recent quarters above that range.
As a supply chain disruption it starts to normalize through the end of 2020.
Cash taxes to be paid are expected to be higher due to the 2022 taxable earnings levels and the runoff of our Nols.
Given the mix of earnings we are now expecting our effective tax rate to be in the 26% to 28% range lower than the previous rank.
We expect that other operating cash expenses will be a cash use of $30 million to $60 million for the year versus the significant source in 2021 and in line with our accruals and cash flow.
$130 million to $140 million of capital expenditures for 2022.
Consequently, we are targeting net free cash flow of $400 million to $450 million for 2022, which is approximately a 41% conversion from adjusted EBITDA.
We expect to continue with our commitment to return capital to shareholders charter getting a multi year average return of 20% to 30% of adjusted net income.
Our record results for the quarter reflect solid execution of our strategies throughout the company as we seek to take full advantage.
Okay build on our momentum and remain focused on growth.
We are confident in our outlook for the full year 2022 and beyond.
I'll again emphasize that our teams everyday continue to drive strong performance in challenging environments and are very committed to achieving our goals.
David.
Thank you Nick.
We're excited about the progress of our business strategy and continued growth in our market share supported by new products, Although I would say.
<unk> Trust with a net worth of tenants chemical engineers.
Food Science system application development professionals can successfully address growing trends.
In March we opened the latest flagship innovation location in our solution Center network in Essen, Germany.
This state of the art facility will serve our European and global customer base across several industries through product formulation benchmark prototyping product performance testing and efficacy product analysis shelf life testing and more.
Our team of chemists and scientists bring specific expertise in beauty and personal care home care and industrial cleaning pharmaceutical ingredients and closings, while being able to network with a global paid is to develop the latest spoke solutions.
This location will also be used to help our customers and suppliers tackle opportunities to develop more sustainable and clean formulations.
We recently created a new global senior leadership role overseeing all sustainable and natural product portfolio.
This world will work closely with our global suppliers and industry experts to identify market opportunities to launch new and innovative ingredients that help our customers address the sustainability regulatory and commercial needs and we'll expand that portfolio.
With our strong earnings and our net leverage at two four times, we continue to evaluate selective bolt on acquisitions as well as continued to target an average capital return of 20% to 30% of adjusted net income to shareholders.
Our commitment to being a digitally that continues unabated as we accelerate the omnichannel approach that is essential in today's hybrid working environments.
We believe our current investments in the three areas of customer acquisition retention and self service are enabling sales growth and reducing our operating costs, while providing a competitive moat against our regional competition.
These investments helped screen line, the customer experience as well as increase our agility and responsiveness to the diverse markets we serve.
And as we do serve diverse markets, we develop experiences and content that are relevant to those market for our suppliers and customers.
We're combining e-commerce capabilities with our industry knowledge and expertise to offer what we believe is an unmatched omnichannel support for prospects and customers no matter, where they are in their product development or purchasing journey.
We extended our digital capabilities to our solution centers to drive innovation and efficiency. So we can get our formulations into the market faster and deliver on a sustained and growing consumer demand. We continued to experience. It's all about the customer.
Looking to enhance the scale agility speed and data driven decision making.
Our digital solution Center is a data driven and powered R&D organization that includes virtual collaborations and webinars extensive custom formulation offering instant access to our project data and tracking formulations successes.
This has enabled a more integrated approach India chemists scientists can connect directly with our suppliers and customers to solve the toughest problems across multiple markets and applications without the time expense and health risks of traveling and meeting in person.
Our digital vision is clear meeting customers wherever whenever and however, they want to engage with us and we are beginning to realize this is a source of sustained competitive advantage.
Putting the customers essentially all we do remains our north star as we continue measuring and getting insights into the customer experience through net promoter score.
Our overall scores through Q1 remained good with improvements over our Q4 performance on our 2021 baseline performance.
This continued improvements in our NPS metric comes despite continued supply chain challenges in the marketplace.
Captured over 3800 responses in Q1, so our NPS process and these insights with shared in real time with us sales and functional teams to drive process improvements.
Combining our NPS metrics with our advanced analytics capabilities, we launched our customer 360 deal of CX 360, <unk> across the U S.
<unk> hundred 68 provides real time visibility of our customers NPS feedback as well as the key performance indicators across several touch points, but allow us to better understand the customer experience and our areas of opportunity.
We're on track to release this tool to a Canadian and Latam businesses in Q2.
Additional predictive work is underway to equip our sellers and managers with proactive insights that highlights our potential areas of opportunity, allowing us to get ahead of an issue and address it proactively.
Altogether, our digital investments and customer centric approach is designed to maximize the effectiveness and scale of our operations to link data into strategic assets, making us an all round easier and Thats a business partner.
Moving to ESG, we've made strides with our agenda and outlined a clear path towards carbon neutrality by 2050.
Evidence of our progress includes the following <unk>.
Continued investments in energy efficient technologies, and hybrid and electric vehicles to reduce our carbon footprint in line with our net zero commitments.
Being recognized by Great place to work Mexico is one of the best workplaces for women.
Being awarded new supplier authorizations variety, but more environmentally friendly ingredients and solutions.
Continue to put safety first which is evidenced by our world class safety record.
And continuing to advance our diversity equity and inclusion goals.
ESG is a priority for us understanding that its our home our responsibility.
Such as each of our core values and aligns with our vision to redefine distribution and be the most valued chemical and ingredient distributor on the planet as well as being better stewards of the Earth's resources.
We look forward to sharing more about our ESG journey next quarter. After the release of our latest annual report.
So before we come to your questions and to summarize.
We delivered record Q1 results and expect a strong second quarter results.
Although the second half of the year contains uncertainties, we are confident in our strategy execution and operating agility and increased our expected 2022 full year adjusted EBITDA guidance in the range of one to $1 <unk> $5 billion with resulting net free cash flow between 400 and 450 million.
<unk>.
Additionally, we expect to bring forward, our 2024 financial targets into 2023, a year ahead of schedule, including delivering adjusted EBITDA margins greater than 9% and 50% net free cash flow conversion.
We plan to use that cash to fund growth initiatives through a combination of high ROI capital investments selective opportunistic bolt on acquisitions and return of capital to shareholders.
We believe we are perfectly positioned to deliver enhanced shareholder value, while fulfilling our purpose and commitment to our people and communities.
Thank you for your attention and your interest in Univar solutions, Please stay healthy and safe and with that we'll open it up for your questions.
Thank you at this time, if you would like to ask a question. Please press Star then the number one on your telephone keypad. If you would like to make sure. Your question. Please press star followed by K. Please limit yourself to one question and one follow up please hold while we compile the Q&A roster.
Our first question today comes from the line of Steve Byrne with Bank of America. Steve. Please proceed with your question.
Yes. Thank you I'm wondering if three months ago. David you thought you were going to just kind of a leap over the 10% EBITDA margin jumped 11%.
If not.
Would you attribute that.
<unk>.
The key driver to that.
And I wonder if.
Sure.
Front of inflationary environment that we're in that.
We carry about a month's worth of inventory perhaps.
It's kind of a lag in it.
And in place scenario environment, a key driver of that.
If we didn't have that if it were more static or do you think the margins would have been.
Hey, good morning, Stephen Thanks for the question.
I mean first first out of the gate, which this transformed this business over the last three years.
Built a really formidable competitive moats and putting the customer at a sensible we do we think it really sets the stage for silicon shareholder value in the future.
But I didn't think we'd LIFO the tenant go straight to <unk> 11.
But I'm very glad that we did were really executing incredibly well the team's performing incredibly well.
Clearly market conditions changed little bit from what we saw three months ago. I mean, we have chemical price inflation above and beyond our expectations and thats, partly offset by variable compensation will go very diligent W. Asinine managements, we have an environmental recovery of $9 million, which helped I think as Nick mentioned.
In his prepared remarks, we had.
<unk> to $110 million of price inflation, we've seen in the first half.
Probably.
Half of that within the within the first quarter and Thats, a little more than we anticipated when we gave guidance, but I think as we as we go through the rest of the year, we will see that EBITDA margin dropped a little bit, but we'll end up well over that 9% target, which we set in our F. 'twenty three goals, which means that we will have achieved and exceeded.
Both those F 22 goals that we set out a couple of years ago. So we're very excited by that with very.
<unk> bye.
Our.
<unk> ability to execute the biopsies of the forming and really.
In a very difficult.
Reduced market environments, we think that we can do well on whatever the scenario.
And if I could follow up your comment about.
Variable comp is that really that senior management comment or how broad is that and the reason I ask is.
I recall years ago, you really change the way the sales organization more is incentivized.
But I'm not sure how much control they have over pricing, but it is some of this.
Comp is driven by the sales organization also pushing price and profitability.
It's spread across the whole business I mean, it isn't just it isn't just made.
Spread right down through the whole business.
It takes a village to get the kind of results that we that we do.
So over.
Half of our Pea protein quality in some way and describe a compensation scheme.
We spread it.
Right the way down through the organ.
And I am absolutely thrilled for them.
Taken in their results.
And being paid for the results that the hard work over the last.
345 years.
Bonds.
Okay, great. Thank you.
Our next question comes from Josh Spector with UBS. Please.
Please go ahead with your question.
Good morning. This is lucas by runoff because you wash.
So I just kind of wanted to talk about.
You're increasing set of trying to bring forward a lot of set targets for next year. So just sort of what is the biggest driver of your higher confidence that 2023.
We haven't been a worsening macro picture at the moment, that's why we sort of now the right time to pull the target forward and just in terms of your pricing assumptions for next year. So you flagged kind of the $100 million to $110 million EBITDA benefit this year, how youre hitting that reverses next year or what are you kind of.
Your expectations on that side as well thanks.
Okay. Lucas Thanks, Thanks for the question good morning.
I think that we have.
We accept we expect prices to stabilize through the second half of the year, which is why we we think that pricing benefit really is just in the first half of the year, but I mean why are we springing. Our 'twenty three goes into 2024 already because we were very confident in our execution.
Executing really well on our strategy and thats evidenced by our share gains new authorizations that digital digital tools that enable us to manage through price changes.
We're very confident in our on our abilities there, but we're very confident in our ability to deliver cost productivity and value capture and I think we're looking at all these things really gives us the confidence to say, yes, we want to really stay such as something we can be in the 24 go into 2023.
Our business is now really just so solely.
Focused on our customers.
We just don't have anything else to do except focus on the customer and focus on growth.
<unk> of all we do not really we think gives us a clear path to deliver long term shareholder value.
Alright, Thanks, and then just on the ingredients the specialty sales force in the U S sort of noted that that was pretty similar to the base chemicals drive.
There's some sort of differences there under the hood.
So with that.
Or is there a difference in volumes.
Does.
Specialty chemicals that lower in the dice, Kansas, just getting more benefit from the <unk>.
Temporary crossing.
I mean, we grew our volumes in the U S, 4% year on year in the quarter and a tight market.
LTE market, I think thats pretty pretty pretty good.
Our growth in ingredients and specialties.
Is that largely driven by.
The new supplier authorizations as well as then good operating performance by our team in the field and so they're growing very well, we see lots of opportunities there, particularly as those customers are looking to reformulate into more sustainable solutions that we see a great transition.
Although the chemicals and services guide.
We have plenty of opportunities, it's a really strong business, it's a very local business.
And if you think about what we're doing in energy and water treatment and some of the other.
Key markets chemical manufacturing, it's a very strong business. So we should expect to see growth across both those sides of the house.
Great. Thank you.
Okay.
Our next question is from Kevin Mccarthy with vertical research partners.
Kevin Your line is open.
Yes. Good morning. Thank you David if I look at your EMEA segment profit trends.
The interest around the sequential uplift there was more or less level, what we would normally see on a seasonal basis.
And I guess that would be despite your exit from Russia. So can you speak to what drove that.
Sequential surge to $64 million of EBITDA in EMEA segment.
Yes, good morning, Kevin look I think the.
The the business in EMEA.
The team there good solid team that's been together for a while and.
<unk> executed incredibly well.
So all in all the difficulties of supply chain that we see in the U S. We also see in EMEA, having our own fleets in large parts of EMEA health Susan drives advantage as the Ingrid.
The increase in specialty business, which was a larger proportion of the business in EMEA than it is in the U S is a very sticky business with high retention.
And that business is doing incredibly well at the moment, so whether it's beauty and personal care, whether it's food ingredients, whether it's pharmaceutical ingredients. The teams are really performing exceptionally well.
In a market that's growing well so were thrilled with the growth rates that we're thrilled with the growth rates.
Overall, I mean that very strong overall.
And.
We'll see.
When other people report, but I think there is there is good if not better than most people in that space I think that it seems there are just performing.
Incredibly well.
Kevin its Scott Nick just also add on the Russia comment as well.
As we noted Russia was a negligible impact on the business. So that was not a factor in the performance.
Okay, and then second question I wanted to ask about cap of north of $1 billion of EBIT leverage is running.
So on a pro forma basis.
If I look at 2020.
Two as a forecast anyway, and so in that in that context can you speak.
Two a potential to establish a dividend and then be the pace of repurchases I was little surprised you are just looking to hold the share count about flat this year.
And that includes assessing the dividend during 2021.
On our focus was maintaining that strong liquidity and deleveraging and we're very pleased with our progress as we now come into 2022 have already figured out F. 'twenty two target with a two five times net leverage and I think we want to continue to invest really for growth. So it's a high ROI capital projects as well.
As for accretive.
Tuck in M&A opportunities.
We're in a position to turn capital to shareholders and we got that $500 million stock buyback program in place and I think we bought under the $24 million in this quarter a $50 million in Q4 of last year. So so we are progressing with that but the board will continue to look at that capital.
Rotation strategy, but we really want to try and prioritize allocating capital, putting putting putting capital to work.
For growth.
That's a key priority for us.
Thank you.
Okay.
Our next question is from David <unk> with Deutsche Bank, David. Please go ahead.
Hi, Good morning, and just for Q2, EBITDA, Cambridge, there quarter over quarter decline from Q1.
The entire light duty.
And we will price deflation and if so how much is that given that seasonally stronger demand in Q2.
Yes. So if you remember in Q1, we had about $9 million in amount of environmental.
And then.
Something around 60, maybe $65 million, but pricing benefit we think that will be less in the second half, we think there'll be a 100, hundreds and mostly in the first half. So we think it will be less.
In the second half, we won't have the environmental recovery, but we'll have some offset from seasonality. So that's how we're thinking about it.
Thanks, and then just on the acquisition I know there are some assets out there in the market, but would you consider acquisition opportunities outside of great intense, especially.
We are looking at acquisitions.
Firstly they.
They can add value to our portfolio.
That could be.
Ability to leverage our footprint leverage our assets out a new geography.
I'll add.
Some chemistry or technology that you don't have already so we will consider acquisitions rights across.
The pace, but where we have.
A really large installed asset base.
Anything outside of the <unk> acquisition.
Physician would be ready to look at how we how we leverage the footprint better. So we are going to be very disciplined in what we look at in how we acquire and I think that we now have a balance sheet, which allows us to do some acquisitions, which is fantastic and having transformed the business with our largest acquisition ever done in R&D.
History on three years ago, we have a muscle memory of how to integrate these very well.
So we think that we are.
Good host for.
Or any potential M&A opportunity and very excited about some of the things that we're seeing out of that.
Thank you.
Our next question comes from the line of Laurence Alexander with Jefferies.
Please go ahead with your question.
Good morning, it's Dan Rizzo on for Laurence.
You did talk a bunch about acquisition and doing bolt on so I was wondering if theres still divestitures that youre looking at too. If you can still kind of cherry pick business lines that don't really fit into what your core growth strategies.
Good morning, Dan.
Let me be done mostly divestitures that we want to do we went through that program.
Lots of the X 22 program.
We consistently we'll look at our assets and see whether there is anything there, which doesn't really fits in that tight.
Chemicals and ingredients space, but at the moment, we're pretty happy with the asset footprint that we have.
Okay and then.
With the share gains is there a target you have every year.
200 basis points that you expect to add to growth share gains or is it kind of more open than that.
Well, yes, I mean, I'm not going to stop if we got more than 100.
We look I mean, I think the first thing is what we look at.
Is how can we be easier to buy from and so we're consistently looking at ways to make the customer experience better which is why our NPS scores in <unk> hundred 60 is so important for us because we want to drive share growth through customer preference.
And make it a good buying experience for customers when they do come to us, but that also means that we need to operate really efficiently and effectively and I'm really.
Pleased with the way we're executing these days, which gives me the confidence to bring those 'twenty three targets sorry, 'twenty four targets forward into 2003, so really it's about.
Operational excellence, it's about having a better buying experience be easy to buy from having the omnichannel approach. So we can meet customers wherever whenever and however, they want to interact with us and we said that we want to grow on iron <unk> business, a couple of hundred basis points ahead of.
General economic consensus and our CNS business at least the general economic consensus if not 100 basis points practice lovaza kind of guidelines that we set for ourselves, but really it's about prisma plus with the central role we do.
Having that that that's a customer experience that drives customer preference and having a customer preference then really drive share growth then so far we're being pretty successful at that.
Sufficiently confidence in the way the whole organization is our pricing to be able to put those targets out there for the next.
18 months or so.
Thank you very much.
Our next question comes from Mike might have been with Barclays. Mike. Please go ahead.
Great. Thanks, Good morning, guys and congrats on a good start to the year.
I just wanted to circle back on the back half EBITDA outlook midpoint of <unk>, 280, which would imply something like $2 15 per quarter in the back half. So is that mostly pricing benefit in the first half falling off but I think in your comments, maybe you are a bit more conservative just starting the year around kind of what second half might bring in Europe .
Incremental color around how you built that out would be helpful.
Sure.
Good morning, Mike Thanks for the question.
Yes, I think we did we highlighted firstly that we think that the extra pricing benefits will be in the first half of the second half the pricing will normalize more in the second half.
But also recognize that if we're paying higher variable compensation, that's ratable across the year, so there'll be a little more.
That in the second half.
Versus the incremental margin.
Also look the world is very uncertain place at the moment and so we're trying to be.
Conservative on on how how the World is we don't expect we don't anticipate a recession in the U S.
We may see some slowdown in Europe that looks very likely so we're trying to build that into our thinking as well.
But I mean, the world is very uncertain that second half, but what we're not uncertain about is our ability to execute we're very confident in our ability to execute which is why we're able to.
Increase the guidance for the full year higher than then we come out of the blocks within the first quarter and we feel very confidence and more out of the market conditions, we will be able to do well, but we have to be conservative given the nature of the world at the moment.
Makes perfect sense, and then secondly, I just wanted to ask in your sales trends are on slide five and the new matrix here Super helpful by the way.
Obviously price is meaningfully amplifying effect in the quarter. So I was hoping you can maybe help us better understand kind of price versus volume or even just kind of how your volumes grew relative to the individual markets here.
Sure I think overall volumes are up slightly in the U S are up 4%.
In EMEA that down, but thats, what the disposal of the update the businesses early last year, I mean supplies, though we still tight supply is very constrained.
So to be able to grow our volumes it's hole.
<unk> demonstrates a.
The fabulous supplier relationships that we have.
I'm, so grateful that that chooses to supply us when when productivity is tight and we have great supplier relationships and Thats playing out and then the effectiveness of our sales organizations.
Overall volumes are slightly up but I think most notably in the U S are up 4% which is.
Which is obviously a big driver.
Great. Thank you.
Thanks for all the questions we have for today, so I'll hand, the call back to the management team for concluding remarks.
Thank you, ladies and gentlemen for your interest in unified solution. If you have any follow up questions. Please reach out to the Investor Relations team. This does conclude today's call.
Okay.
Thank you everyone for joining us today. This concludes our call you may now disconnect your lines.
Yeah.
[music].
Okay.
Okay.
Okay.